Rationale: Glucagonoma is an uncommon disease but it has been associated with a pattern of symptoms defined as glucagonoma syndrome. These symptoms, if promptly recognized, could help to speed up the diagnosing process.
Introduction
In this article, we report a case of a 68-year-old woman presenting with a glucagonoma syndrome.
She had a recent history of abdominal pain, cutaneous rash, and weight loss. She had a history of diabetes mellitus and hyperlipidemia. Her laboratory exams demonstrated elevation of liver function tests. She underwent abdominal contrast-enhanced computed tomography (CT), which showed multiple hypervascular liver masses with central necrosis and a nodule in the pancreatic tail. [1] [2] [3] An ultrasound-guided liver core-biopsy was performed and consistent with well-differentiated neuroendocrine tumor (glucagonoma). Her blood glucagon levels were elevated. [4] Thereafter, the patient underwent SPECT/CT with OctreoScan ( 111 In-pentetreotide), which demonstrated elevated uptake in both pancreatic and liver masses indicating that the lesions express high densities of somatostatin receptors. [5, 6] The patient was initially treated with long-acting somatostatin analogs.
Case presentation
Written informed consent for this case report was not required, as established by our institutional review board polices. A 68-yearold woman presented with a recent history of abdominal pain, cutaneous rash, chronic fatigue, and weight loss. She had a past medical history of diabetes mellitus, hyperlipidemia, gastroesophageal reflux disease, irritable bowel syndrome, and arthritis. In the previous months, she referred some dyspnea on exertion and diarrhea. Her laboratory exams demonstrated elevation of liver function tests: Alkaline Phosphatase 289 (reference range 45-129 Units/L); AST 94 (reference range 10-37 Units/L) ALT 178 (reference range 5-37 Units/L). Her diabetes was uncontrolled for the previous months. On physical examination, she had dry mucous membranes, tachycardia, hepatomegaly and skin erythema localized to the lower abdomen, buttocks, and distal extremities. Given these abnormalities, she underwent a contrast-enhanced computed tomography (CT) of the abdomen which showed multiple hyper-vascular liver masses with central necrosis, measuring up to 14.5 cm (Fig. 1 , white arrow) and a 4.0 cm nodule in the pancreatic tail (Fig. 1, dashed white arrow). [1] The liver was enlarged to 26 cm. There was no intrahepatic or extrahepatic dilatation. An ultrasound-guided liver core-biopsy was performed and demonstrated relatively uniform, round tumor cells with stippled chromatin and inconspicuous nucleoli arranged in diffuse sheets or nests, with a low mitotic activity (<1 mitosis/10 high-power fields) ( Fig. 2A) . Immunohistochemical stains demonstrated that the tumor cells were positive for CK AE1/AE3, CK20, chromogranin, synaptophysin, and glucagon ( Fig. 2B ). These findings were consistent with metastatic well-differentiated neuroendocrine tumor (glucagonoma). Her plasma glucagon was tested and was highly elevated to 1154 (reference range < 134). Thereafter, the patient underwent SPECT/CT with OctreoScan, which demonstrated uptake in the pancreatic tail lesion consistent with primary neuroendocrine tumor (Fig. 3 white arrow) and extensive octreotide avid masses in the liver corresponding to metastases (Fig. 3 asterisks) , indicating that the lesions over-expressed somatostatin receptors. [3] The patient started treatment with dacarbazine, with an excellent clinical response. After 6 cycles, dacarbazine was stopped and she was treated with long-acting somatostatin analogs. Four years after the disease onset symptoms started worsening, with development of confusion, weakness, upper quadrant pain, and constipation. Blood tests showed elevated ammonia, bilirubin, and leukocytosis. A magnetic resonance imaging (MRI) scan showed the increased size of hepatic metastases compared to previous studies ( 
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Medicine including hepatic arterial embolization, 5-fluorouracil (5FU), and platinum based treatment were tried. Unfortunately, none of these was successful and the patient passed away in a couple of months. This aggressive "malignant transformation" was predicted by her DNA next-generation sequencing (NGS), which showed mutations in ERBB2, KRAS, NRAS, and TP53.
Discussion
The first description of glucagonoma is attributable to Becker et al. [7] Glucagonoma is a rare pancreatic neuroendocrine tumor (PNET) of the alpha cells of the pancreas. As recently defined by World Health Organization (WHO), only functioning tumors can be defined as glucagonomas, differentiating them from nonfunctioning pancreatic alpha-cell tumors. [8, 9] Glucagonoma are associated with characteristic symptoms which can help making a prompt diagnosis: weight loss (10-15 kg), necrolytic migratory erythema (a characteristic but not pathognomonic red, blistering rash), diabetes mellitus, [10] anemia, venous thromboembolism, depression, and diarrhea. [4, 11, 12] This cluster of symptoms it is often referred to as glucagonoma syndrome. The literature reported incidence of glucagonoma is 2.4/ 100,000,000, even if many studies do not differentiate between functioning and not functioning alpha cell tumors. [2] It affects the 6th decade of life, but the age range is wide, from 15 to 90 years, with no predilection for sex. [13] The etiology is not yet fully understood, genetic factors may play a role. There is a strong association with a familiar history of multiple endocrine neoplasia type 1 (MEN 1). [14] This tumor is usually aggressive, with the cancer spreading and getting worse, but even if metastatic, the overall survival has been reported to be long, with a mean life expectancy reported ranging from 3 to 8 years. [15] Most of the cases reported in literature were already metastatic at the time of the diagnosis, with a long period between the onset of symptoms and the final diagnosis. An early diagnosis would allow for curative resection treatment. For this reason, it is important to highlight the classic symptoms associated with glucagonoma. [11] The imaging role is to localize disease, once clinically suspected. [16, 17] Ultrasonography is not specific nor sensitive and has a low negative predictive value. [18] The most frequent anatomical site is distal part of the pancreas (90% body and tail) making the US identification even more difficult. [9, 19] Tumor presence and localization is invariably documented by CT scan. [19] Secreting islet tumors and their metastasis are most commonly hyper-vascular with a definite enhancement during the contrast arterial phase. [20] Confirmation and staging of diseases can be performed in all patients by SPECT/CT OctreoScan with 111 In-pentreotide (Somatostatin Receptor Scintigraphy -SRS), [21] [22] [23] [24] and more recently with 68 Ga-DOTATATE PET\CT. [6] Another useful purpose of performing SRS is the evaluation of the functional state of the tumor and of the secondary localization, thus providing suitability for therapy with peptide receptor radionuclide therapy (PRRT). [22, 25] Treatment may vary on stage of disease. If possible surgical resection and debulking procedures are performed. [26] Control of symptoms is almost always possible at the early stages of disease with stomato-statin analogs (SSA). [15] PRRT with 177 Lu DOTATATE has been proposed as a first-line therapy in patients with glucagonoma and secreting metastasis. [5, 27, 28] However, since the number of people affected by glucagonoma is too small, it has not yet been possible to draw results on the actual benefit of this therapy, especially in terms of long-time survival. [29] 
